Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2005
Revised Date: 
December 2019
  • Used concurrently with oxazophosphorine antineoplastic agents (cyclophosphamide, ifosfamide) to prevent urinary tract toxicity (ie. hemorrhagic cystitis).
Reconstitution and Stability: 
  • Store at room temperature
  • Available as a 100 mg/mL solution, with or without preservative
  • WITH preservative: stable 48 hours refrigerated if diluted in D5W or NS
  • WITHOUT preservative (Uromexitan): stable 24 hours room temperature diluted in D5W, NS or combinations

- Solutions Compatible: D5W, NS and combinations

- Additive/Above Cassette Compatible: ifosfamide, cyclophosphamide

- Y-site Compatible: allopurinol, filgrastim, fludarabine, methotrexate, ondansetron, potassium chloride, sodium bicarbonate (diluted), TPN (amino acids/dextrose -non-acetate containing)

Incompatible: amphotericin B, cisplatin, carboplatin


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct YES
Usual dilution: 20 mg/mL
Infusion time: 2-5 minutes
IV Intermittent Infusion YES
Usual dilution: 1-20 mg/mL
Infusion time: 15 -30 minutes
IV Continuous Infusion YES, in sufficient volume to go over 24 hours




(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • Dose of mesna is expressed as a percentage of oxazophosphorine dose given: dosages range from 60 to 160% of the total oxazophosphorine dose
  • 25% of the total mesna dose is given concurrently with ifosfamide or cyclophosphamide and the remainder can be given as an infusion over 8-12 hours or a three bolus doses Q 3-4 H.

Note: For children < 12 kg, use preservative free mesna

Potential hazards of parenteral administration: 
  • Nausea, vomiting
  • Diarrhea, abdominal pain
  • Thrombophlebitis and irritation at injection site (rare)
  • Transient drop in blood pressure, pulse
  • Taste disturbances
  • May cause false positive reactions in tests for ketone bodies in urine
  • Oral mesna dose = double IV dose

1. Fresenius Kabi Canada Ltd. Product Monograph: Mesna for injection: Last revised: 30July2019. Accessed:    2Oct2019

2. Baxter Corporation. Product Monograph: Uromexitan. Last revised: 6Aug2013. Accessed: 2Oct2019

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.